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Abstract The PDE4 catalytic machinery comprises, in part,
two divalent cations in a binuclear motif. Here we report that
PDE4A4 expressed in Sf9 cells exhibits a biphasic Mg2+ dose^
response (EC50 of V0.15 and s 10 mM) in catalyzing cAMP
hydrolysis. In vitro phosphorylation of PDE4A4 by the PKA-
catalytic subunit increases the enzyme’s sensitivity to Mg2+,
leading to 4-fold increased cAMP hydrolysis without affecting
its Km. The phosphorylation also increases the potencies of
(R)- and (S)-rolipram without affecting CDP-840 and SB-
207499. The results support that modulating the cofactor
binding affinity of PDE4 represents a mechanism for regulating
its activity. ß 2002 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
3P,5P-Cyclic nucleotide phosphodiesterases (PDEs) are met-
allohydrolases that catalyze the hydrolysis of cAMP and
cGMP. In concert with multiple adenylate cyclases, 11 fami-
lies of PDEs regulate cAMP and cGMP-mediated signaling in
speci¢c tissues and subcellular locations [1]. The cAMP-spe-
ci¢c PDE4s, encoded by four genes (A^D), are the major
regulator of cAMP metabolism in most in£ammatory and
immune cells [2^4]. PDE4 inhibitors are e⁄cacious in clinic
trials for the treatment of asthma and chronic obstructive
pulmonary disease (COPD) [4^6].
Each of the four PDE4 genes encodes multiple proteins that
share identical catalytic and C-terminal domains but di¡er
near their N-termini. Two upstream conserved regions
(UCR1 and UCR2) are located between the divergent N-ter-
mini and the catalytic domains of the longer variants. Shorter
variants lack the UCR1 domain [3]. The divergent N-termini
contain signals for compartmentalization and protein/protein
interactions, thereby allowing the ¢ne-tuning of cAMP signal-
ing to discrete subcellular locations and speci¢c pathways
[2,3]. This is exempli¢ed by the identi¢cation of the PDE4/
anchoring protein/PKA signaling complexes [7,8].
Intracellular cAMP concentrations £uctuate transiently
within a narrow range upon receptor stimulation [9]. In addi-
tion to desensitization at the receptor and cyclase levels, phos-
phorylation-mediated PDE activation plays a pivotal role in
regulating the transient changes of cAMP concentrations [10^
15]. Elevated PDE3 and PDE4 activities, resulting from PKA
activation, have been implicated in the short-term feedback
regulation of cAMP concentrations in platelets, adipocytes,
myoblasts, aortic smooth muscle cells, osteoclasts and U937
cells, indicating the ubiquitous nature of the mechanism [16^
23]. At the molecular level, phosphorylation of the conserved
RRES motif in UCR1 is responsible for the PKA-mediated
activation of PDE4D3 by relieving an inhibitory constraint
from the UCR1 and UCR2 domains on the catalytic machi-
nery [18,24^27]. An Erk2-mediated phosphorylation of the
conserved SPS motif, which lies at the C-terminal of the
PDE4 catalytic domain, regulates the activities of PDE4B,
4C and 4D di¡erentially [28^30]. Structurally, a tightly bound
M1 (likely Zn2) and a readily exchangeable M2 ion (Mg2
preferred) in a binuclear motif constitute the central feature of
PDE4 catalytic machinery [31]. The metal ions are responsible
for eliciting the high a⁄nity cAMP binding, providing the
hydroxyl nucleophile and facilitating AMP release from the
active site [31^33]. An active site conformational di¡erence in
the presence and absence of the cofactor ions leads to the
di¡erential binding of inhibitors including the high and low
a⁄nity binding of 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-
pyrolidinone (rolipram). Both cofactors of the holoenzyme
(M1/M2-bound PDE4) appear to be involved in mediating
the high a⁄nity rolipram/PDE4 interaction. In their absence,
rolipram binds to the PDE4 apoenzyme with a KdV150 nM
[33]. The involvement of the metal ions in PDE4 catalysis
suggests that modulating the cofactor binding a⁄nity repre-
sents a mechanism for its activity regulation [6,24,32,33]. This
is supported by a biphasic Mg2 response and an increased
Mg2 sensitivity upon the Ser54 phosphorylation of PDE4D3
[18,24,26].
Herein we report that human PDE4A4 expressed and par-
tially puri¢ed from Sf9 cells also exhibits a biphasic response
to Mg2. PKA-mediated further phosphorylation of PDE4A4
results in a 4-fold increased activity, resulting from an in-
creased Mg2 sensitivity. In addition, PDE4A4 phosphoryla-
tion selectively increases the sensitivity of the enzyme to both
enantiomers of rolipram.
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2. Materials and methods
2.1. Chemicals
[3H]cAMP, PDE-SPA1 beads and diethylaminoethyl^Sepharose
(DEAE^Sepharose) (Fast Flow) were purchased from Amersham
Pharmacia Biotech. The catalytic subunit of PKA was purchased
from Boehringer Mannheim. PDE4 inhibitors were synthesized at
Merck Frosst. Other chemicals were purchased from Sigma/Aldrich.
2.2. Expression and puri¢cation of PDE4A4
Human PDE4A4 was expressed using the baculovirus/Sf9 expres-
sion system and was partially puri¢ed on a DEAE-cation exchange
column using a linear KCl gradient following procedures similar to
that described previously [34,35]. Protein concentration was estimated
with BSA as standard using the Bio-Rad protein assay kit.
2.3. PKA phosphorylation of PDE4A4
The partially puri¢ed PDE4A4 (40 Wg) was incubated with the
catalytic subunit of PKA (300 units) for 2 h at room temperature in
a bu¡er (300 Wl) containing 50 mM Tris (pH 7.5), 1 mM EDTA, 10
mM MgCl2, 200 mM NaCl, 2 mM N-K-benzoyl-L-arginine ethyl ester
(BAEE), 2 mM benzamidine, 0.2 mM DTT and 300 WM ATP. Phos-
phorylation was stopped by the addition of excess EDTA (15 mM)
and the sample was stored at 380‡C.
2.4. PDE activity assay
PDE4 activity was monitored by the hydrolysis of [3H]cAMP to
[3H]AMP using the PDE-SPA kit from Amersham Pharmacia Biotech
as described previously [32]. The assay mixture contained 100 nM
[3H]cAMP (1 WCi/ml) in a bu¡er containing 20 mM HEPES (pH
7.5), 10 mM MgCl2, 1 mM EDTA, 100 mM KCl and 2 Wl of test
compound in DMSO at 30‡C. The reaction was initiated by the ad-
dition of enzyme for 10 min. The potency of inhibitors (IC50 value)
was determined from an 11-point dose^response curve performed in
duplicate. The Mg2 dose^response was determined at 0.1 WM
[3H]cAMP using bu¡er treated with the K-form of the Chelex beads
(Bio-Rad) to remove trace metal ions as previously described [34]. The
ionic strength of the ¢nal assay solution was maintained at 150 mM
using KCl with no speci¢c ion e¡ects observed for either K or Cl3
ions.
2.5. Data analysis
Data were expressed as mean þ S.E.M. of nv3 independent experi-
ments unless otherwise speci¢ed. Dose^response curves and IC50 val-
ues were analyzed by a non-linear iterative regression routine using
Gra¢t1 (Erithacus Software).
3. Results
3.1. PKA phosphorylation-mediated PDE4A4 activation
Human PDE4A4 was expressed using a baculovirus/Sf9 ex-
pression system and partially puri¢ed on a DEAE column.
Upon elution with a linear KCl gradient, a single rolipram-
sensitive PDE activity peak, paralleled by a single immunore-
active PDE4 band, was obtained with PDE4A4 accounting
for V10% of the total proteins by SDS^PAGE analysis under
denaturing condition (Coomassie stain). In vitro phosphory-
lation of the partially puri¢ed PDE4A4 was conducted using
the PKA-catalytic subunit in the presence of 0.3 mM ATP
and 10 mM MgCl2. Fig. 1 shows its PDE activity^cAMP
concentration response before (O) and after (a) PKA/Mg-
ATP treatment at 0.5 mM Mg2. The apparent Vmax value
increased by 4-fold (from 0.2 to 0.8 Wmol/mg/min) after the
PKA/Mg-ATP treatment with a slightly reduced apparent Km
(from 3.2 to 2.2 WM). Incubation with either the catalytic
subunit or ATP alone exerted negligible e¡ect on the PDE
activity. No PDE4A4 degradation was detected during the
phosphorylation procedure by Western blot analysis. Phos-
phorylation of PDE4A4 was con¢rmed by the detection of a
radiolabeled PDE4A4 using [32P]ATP. In contrast to the re-
duced mobility observed with Ser54-phosphorylated PDE4D3
on SDS^PAGE [26], PDE4A4 phosphorylated from the PKA/
Mg-ATP treatment comigrated with PDE4A4 under a variety
of conditions tested.
Fig. 2 shows the PDE activity^Mg2 dose^response of
Fig. 1. PDE4A4-catalyzed cAMP hydrolysis at increasing cAMP
concentration before and after PKA/Mg-ATP treatment. Hydrolysis
of [3H]cAMP at increasing cAMP concentrations by PDE4A4 be-
fore (O) and after (a) PKA/Mg-ATP treatment was determined in
a bu¡er containing 20 mM HEPES (pH 7.5), 0.5 mM MgCl2 and
100 mM KCl at room temperature. The values represent the mean
( þ S.E.M.) of three measurements. Saturation analysis yielded the
Km values of 3.2 ( þ 0.2) and 2.2 ( þ 0.2) WM before and after the
PKA-mediated activation. The apparent Vmax values were at 0.2
( þ 0.03) and 0.8 ( þ 0.1) Wmol/mg/min respectively for the partially
puri¢ed PDE4A4 (V10% pure from Coomassie stain on SDS^
PAGE).
Table 1
Potency of inhibitors against PDE4A4 before and after PKA activation compared with their Mg2-dependent and -independent binding a⁄n-
ities against GST^PDE4A248
Compound Inhibition of catalysis (IC50, nM)a Binding a⁄nity (IC50, nM)b
PDE4A4 PDE4A4PKA (10 mM EDTA) (5 mM Mg2)
(R)-Rolipram 123 ( þ 30) 8 ( þ 3) 150 ( þ 37) 5 ( þ 1)
(S)-Rolipram 580 ( þ 50) 120 ( þ 15) 290 ( þ 68) 64 ( þ 4)
CDP-840 7 ( þ 2) 4 ( þ 2) s 4000 6 ( þ 2)
SB-207499 39 ( þ 5) 45 ( þ 7) s 4000 42 ( þ 7)
aThe inhibitory potencies (mean þ S.E.M., nv3) against the partially puri¢ed PDE4A4 before (PDE4A4) and after the PKA/Mg-ATP treatment
(PDE4A4PKA) were determined in a bu¡er containing 20 mM HEPES (pH 7.5), 1 mM EDTA, 10 mM Mg2, 100 mM KCl and 0.1 WM
[3H]cAMP.
bThe binding a⁄nities (mean þ S.E.M., nv3) of inhibitors against GST^PDE4A248 in 5 mM free Mg2 and in 10 mM EDTA were adapted
from [33].
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PDE4A4 before (O) and after (a) the PKA-mediated phos-
phorylation. The activity was detected using 0.1 WM cAMP
under a constant ionic strength (150 mM) which minimizes
the e¡ect of ionic strength-induced activity changes [27]. Be-
fore the PKA/Mg-ATP treatment, the Mg2 dose^response
was biphasic with high and low a⁄nity responses (EC50) of
V0.15 mM and s 10 mM respectively. Following phosphor-
ylation, the Mg2 dose^response became monophasic with an
EC50 value of 0.11 ( þ 0.04) mM, which resulted in V4-fold
increased PDE activity at Mg2 concentrations below 10 mM.
Thus, the PKA-mediated PDE4A4 phosphorylation increases
the enzyme’s sensitivity to Mg2-mediated activation, analo-
gous to that of PDE4D3 [18,23,24].
3.2. Selective perturbation of inhibitor potency
Besides the increased rate of cAMP hydrolysis, in vitro
phosphorylation of the PDE4A4 selectively increased the po-
tency (IC50 value, inhibition of catalysis at 0.1 WM cAMP) of
(R)-rolipram from 123 to 8 nM and of (S)-rolipram from 580
to 120 nM. In contrast, the potency of (R)-(+)-4-(2-(3-cyclo-
pentyloxy-4-methoxyphenyl)-2-phenylethyl) pyridine (CDP-
840) and cis-4-[cyano-4-(3-cyclopentyloxy-4-methoxyphenyl-
(R)-1-cyclohexane carboxylic acid (SB-207499) were mini-
mally perturbed by the enzyme phosphorylation (Table 1).
The Mg2-dependent (5 mM Mg2) and independent (10
mM EDTA) components of PDE4 bindings of these inhibitors
were recently delineated by the displacement of glutathione-S-
transferase (GST)^PDE4A248 (HSPDE4A4B248ÿ886) bound
[3H]rolipram in a SPA binding assay and they are listed in
Table 1 for comparison [33]. After phosphorylation, the po-
tencies of the dual binding rolipram enantiomers against
PDE4A4 approached their holoenzyme binding a⁄nities
with GST^PDE4A248. The potencies of the Mg2-dependent
CDP-840 and SB-207499 were insensitive to the PKA-medi-
ated PDE4A4 phosphorylation.
4. Discussion
The present study demonstrates that in vitro PKA-mediated
phosphorylation of PDE4A4 activates the enzyme by increas-
ing its sensitivity to the Mg2 cofactor. In addition, the
PDE4A4 phosphorylation selectively shifted the potencies of
(R)- and (S)-rolipram, which bind to both apo- and holoen-
zyme, toward their holoenzyme binding a⁄nities. Thus, the
potency of the dual binding inhibitor rolipram is coupled to
the enzyme activation state [32,33]. Although the PDE4
apoenzyme was detected under a stringent metal-free environ-
ment [35], M1-bound PDE4, holoenzyme and their cAMP
complexes likely dominate the distribution of enzyme species
during catalysis. Rolipram binding to the M1-bound PDE4
remains to be determined, which could further the under-
standing of its inhibition kinetics and phosphorylation sensi-
tivity [33].
Several serines were phosphorylated in PDE4D3 upon PKA
treatment, with the Ser54 phosphorylation of the RRES motif
being responsible for its PKA-mediated cellular activation
[18,24]. Phospho-PDE4A4 was detected from a 32P-phos-
phate-supplemented medium, indicating that PDE4A4 ex-
pressed in Sf9 cells is at least partially phosphorylated (un-
published data). PDE4A330ÿ723 and GST^PDE4A248 expressed
in Sf9 cells under similar conditions are extensively phosphor-
ylated at both serines of the SPS motif by mass spectral anal-
ysis [36]. Phospho-peptides that correspond to the phosphor-
ylated RRES and SPS motifs were detected in a tryptic
digestion mixture of the PDE4A4 by mass spectral analysis.
However, the low purity of the enzyme preparation, coupled
with the poor recovery of the phospho-peptides on mass spec-
trometer, has hampered the quanti¢cation of their phosphor-
ylation level. A partially phosphorylated PDE4A4 provides
the simplest explanation for the biphasic Mg2 response in
Fig. 2 and its sensitivity toward PKA-mediated further phos-
phorylation. Prolonged alkaline or acid phosphatase treat-
ment of the partially phosphorylated PDE4A4 from Sf9 cells
both shifted the (R)-rolipram potency to 200^500 nM. The
resulting material after removing the phosphatases on an
ion-exchange column (phosphatases interfere the PDE assay
by hydrolyzing AMP) was unstable and exhibited a similar
biphasic Mg2 response with a much reduced and variable
Vmax value (up to 10-fold). The protein appears to be quite
sticky. Under the same conditions, extensive dephosphoryla-
tions of the SPS motif were detected in GST^PDE4A248 (un-
published data). Therefore, further studies are needed to dis-
sect the e¡ects of the multiple serine phosphorylation.
Previous studies indicate that the PKA-mediated Ser54
phosphorylation in PDE4D3 alleviates an electrostatically
mediated inhibitory constraint on catalysis [25^27]. In addi-
tion to the activation by PKA, high ionic strength (s 300 mM
KCl) activates the partially puri¢ed PDE4A4 by 2^3-fold and
increases the enzyme’s sensitivity to (R)-rolipram, with its po-
tency approaching the holoenzyme binding a⁄nity in 800 mM
KCl and 5 mM MgCl2. Under the high ionic strength con-
ditions, the PDE activity^Mg2 response approaches mono-
phasic (unpublished data). These data support the presence of
a similar inhibitory constraint in PDE4A4. The binuclear ion
center of PDE4 is located at the interface of three subdomains
Fig. 2. PDE4A4-catalyzed cAMP hydrolysis at increasing Mg2
concentrations before and after PKA/Mg2-ATP treatment. The
rate of cAMP hydrolysis at increasing Mg2 concentrations before
(O) and after (a) PKA/Mg-ATP treatment of PDE4A4 was deter-
mined at 150 mM constant ionic strength in a bu¡er containing 0.1
WM [3H]cAMP and 20 mM HEPES (pH 7.5) at room temperature.
The values represent the mean ( þ S.E.M.) of two measurements.
The monophasic Mg2 response (a) has an EC50 value at 0.11
( þ 0.04) mM for Mg2. The biphasic Mg2 response (O) of the
control were simulated using a two binding site model with EC50
values at 0.15 ( þ 0.05) and 100 ( þ 20) mM respectively.
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[31]. It is tempting to speculate that the enzyme’s cofactor
binding a⁄nity may be sensitive to perturbations within these
domains. Modulating the cofactor binding a⁄nity, through
phosphorylations and protein/protein interactions, may repre-
sent a mechanism of PDE4 regulation.
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